Showing results (31-40 of 142) with videos related to

Sort By:
Pageof 15
Oncotargets and Therapy|September 28, 2011
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemiaKimberley A Hoeksema, Aarthi Jayanthan, Todd Cooper, et al.
Thyroid : Official Journal of the American Thyroid Association|November 9, 2010
A postmenopausal woman with gross cystic disease fluid protein-15 and estrogen receptor-positive recurrence of papillary thyroid cancerAmanda Winters, Paul Friedlander, Bernard M Jaffe, et al.
Journal of Correctional Health Care : the Official Journal of the National Commission on Correctional Health Care|February 22, 2023
Implementing Opt-Out HIV Testing in the Alameda County JailsSamantha Feld, Jessica Steele, Shailey Klinedinst, et al.
Case Reports in Pediatrics|March 11, 2017
Vitamin K Deficiency Presenting in an Infant with an Anterior Mediastinal Mass: A Case Report and Review of the LiteratureMauricio A Palau, Amanda Winters, Xiayuan Liang, et al.
Blood|July 2, 2002
Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitroGeorges Lacaud, Lia Gore, Marion Kennedy, et al.
Pediatric Blood & Cancer|July 25, 2023
Children's Oncology Group blueprint for research: Acute lymphoblastic leukemiaElizabeth A Raetz, Deepa Bhojwani, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|June 26, 2014
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumorsRobin E Norris, Suzanne Shusterman, Lia Gore, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2007
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsLaura Q M Chow, S Gail Eckhardt, Cindy L O'Bryant, et al.
Pediatric Blood & Cancer|August 14, 2012
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemiasAbeer Abd Elmoneim, Lia Gore, Rebecca M Ricklis, et al.
Investigational New Drugs|November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumorsAlbiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Pageof 15